Adjuvant endocrine therapy with cyclindependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/ HER2– breast canc

Spring L. M. et al; npj Breast Cancer 2025

Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasi

Foldi J; JCO Precision Oncology 2025

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpas

Mittendorf E. A. et al; Nature Medicine 2025

Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors, a Feasibility Study

Reason E. H. et al; Ann Surg Oncol 2025

Detection and Monitoring of Breast Cancer Local Recurrence Via Circulating Tumor DNA Minimal Residual Disease Assay

Prasath V, et al; JCO Precision Oncology 2025

Circulating tumor DNA refines risk stratification of neoadjuvant therapyresistant breast tumors

Magbanua M. J. et al; Nature Communications 2025

Exploring the utility of ctDNA testing in high-risk breast cancer patients in a community setting: case series

Wong K, et al; Ther Adv Med Oncol 2025

Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR)

Gupta, et al. Transplant International. 2026

Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study

Nakamura Y. Reiter J.G. Natarajan P. et al. npj Precis. Onc. 2026

Surveillance Donor-derived Cell-free DNA Allows for the Safe Reduction in Protocol Transbronchial Biopsies After Lung Transplantation

Kashika Goyal, et al. Transplantation Direct. 2026

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib

Zhang et al. JAMA Oncology 2025

Circulating tumor DNA refines risk stratification of neoadjuvant therapy- resistant breast tumors

Mark Jesus M. Magbanua, et al. Nature Communications 2025

Genetic Testing in the Management of Adult CKD

Chebib, F; et al. Journal of the American Society of Nephrology 2025

ctDNA Monitoring in Ovarian Cancer Patients Receiving PARPi

Toboni, Michael D, et al. Gynecologic Oncology 204 (2026)

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma the rando

Long, Georgina V, et al. Nature Medicine 2025

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

Galsky MD, Gschwend JE, Milowsky MI, et al. Ann Oncol. 2025

Neoadjuvant immunotherapy in mismatch-repair proficient colon cancers

Tan PB, Verschoor YL, van den Berg JG, et al. Nature. 2025

Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1

Using Circulating Tumor DNA–Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer

Ketch et al. JCO PO 2025